Skip to main content
. 2011 May 12;18(6):868–874. doi: 10.1136/amiajnl-2011-000097

Table 2.

Auditable recommendations and proof-of-concept adherence feedback for one ART clinic nurse and one clinical officer from the month of April, 2010

Auditable recommendation Sample adherence for April, 2010
Individual Clinic
% Ratio % Ratio
Nurse
 1. If any symptoms are recorded as YES, then refer to a clinician 33.3 28/84 40.4 415/1027
 2. If fever is recorded as YES, then refer to a clinician 0/0 62.5 40/64
 3. If abdominal pain is recorded as YES, then refer to a clinician 75.0 3/4 46.2 43/93
 4. If vomiting is recorded as YES, then refer to a clinician 0/0 83.3 15/18
 5. If diarrhoea is recorded as YES, then refer to a clinician 33.3 1/3 32.4 12/37
 6. If weight loss is recorded as YES, then refer to a clinician 0/0 85.7 6/7
 7. If rash is recorded as YES, then refer to a clinician 11.1 1/9 60.5 49/81
 8. If leg pain or numbness in your legs is recorded as YES, then refer to a clinician 25.0 8/32 37.2 105/282
 9. If cough is recorded as YES, then refer to a clinician 21.1 4/19 29.1 60/206
 10. If yellow eyes is recorded as YES, then refer to a clinician 0/0 0/0
 11. If any unwanted changes in body shape is recorded as YES, then refer to a clinician 0/0 100 10/10
 12. If any other new symptom is … YES, then refer to a clinician 58.8 20/34 46.5 276/593
 13. If all symptoms are recorded as NO then the patient can be dispensed ARVs 92.2 329/357 84.7 2757/3256
Clinical officer
 14. CPT-eligible patients on CPT 77.3 92/119 89.6 1206/1346
 15. Adult CPT prescription: one tablet (480 mg) twice a day 100 92/92 100 1206/1206
 16. HIV-positive TB patients will start on cotrimoxazole according to the current CPT policy 16.7 1/6 17.8 8/45
 17. Stavudine should not be combined with zidovudine (AZT) due to pharmacologic antagonism 100 85/85 100 1114/1114
 18. All adults will now receive the stavudine-30 mg regimen 100 85/85 100 1114/1114
 19. The drug (lamivudine) should never be given as monotherapy 100 92/92 100 1236/1236
 20. Patients with acute hepatitis (manifested by jaundice) should not be given d4T/3TC/NVP 0/0 0/0
 21. In the case of jaundice or high suspicion of hepatitis with impending liver failure, d4T/3TC/NVP should be stopped 0/0 0/0

ART, antiretroviral therapy; ARVs, antiretroviral drugs; CPT, cotrimoxazole preventive therapy.